OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07(d) of Form 8-K, the Company’s decision as to how frequently the Company will conduct future non-binding, advisory votes to approve the compensation of the Company's named executive officers; and (ii) correct a typographical error regarding the number of votes cast against Proposal 3 set forth in the Company’s proxy statement for its Annual Meeting.

Item 5.07 Submission of Matters to a Vote of Security Holders.

As reported in the Original 8-K, the non-binding, advisory proposal regarding the preferred frequency of advisory approval of the compensation of the Company’s named executive officers, voted on at the Annual Meeting, received the following number of votes:

Consistent with the recommendation of the Board of Directors of the Company as set forth in the Company’s proxy statement for its Annual Meeting and the vote of the stockholders at the Annual Meeting, the Company will include a non-binding, advisory proposalto approve the compensation of the Company's named executive officers in its proxy materials every three years until the next stockholder vote on the frequency of advisory approvalof the compensation of the Company's named executive officers.

In addition, the Original 8-K reported that there were 243,331 votes against Proposal 3 in the Company’s proxy statement for its Annual Meeting. Proposal 3 was a non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement.The correct number of votes cast for and against, the number of abstentions and the number of broker non-votes with respect to this Proposal 3 were as follows:

About OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX)

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.